O
Opus Genetics, Inc. (IRD)
NCM – Real vaqt narxi. Valyuta: USD
5.18
+0.06 (1.17%)
Yopilishda: May 12, 2026, 4:00 PM EDT
5.18
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 4:00 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
5.18
+0.06 (1.17%)
Yopilishda: May 12, 2026, 4:00 PM EDT
5.18
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 4:00 AM EDT
Opus Genetics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, irsiy retinal kasalliklari (IRDs) bo'lgan bemorlarda ko'rishni tiklash va ko'rlikni oldini olish uchun gen terapiyalarini va boshqa oftalmik kasalliklar uchun boshqa turdagi terapiyalarni ishlab chiqadi. U LCA5 bilan bog'liq IRDni davolash uchun 1/2-faza klinik sinovida bo'lgan erta boshlangan retinal degeneratsiya bo'lgan OPGx-LCA5 va BEST1 bilan bog'liq retinal kasallikni davolash uchun OPGx-BEST1ni ishlab chiqadi. Kompaniya, shuningdek, RHO mutatsiyalari keltirib chiqaradigan autosomal dominant retinitis pigmentosani maqsad qilgan gen terapiyasi bo'lgan OPGx-RHO; retinal dehidrogenaza genidagi mutatsiyalar keltirib chiqargan retinal distrofiya bilan og'rigan bemorlarda protein ekspressiyasini tiklash va funktsional yomonlashuvni to'xtatish uchun ishlab chiqilgan OPGx-RDH12; MERTK IRDni davolash uchun AAV vektori bo'lgan OPGx-MERTK; nikotinamid mononukleotid adenililtransferaza 1 genidagi mutatsiyalar keltirib chiqargan retinal degenerativ kasallik bilan og'rigan bolalarda funktsional yomonlashuvni to'xtatish uchun ishlab chiqilgan gen augmenter terapiyasi bo'lgan OPGx-NMNAT1; va CNGB1 genidagi mutatsiyalar tufayli yuzaga kelgan retinitis pigmentosani davolash uchun AAV gen terapiyasi bo'lgan OPGx-CNGB1ni o'z ichiga olgan turli xil preklinik IRD dasturlarini ishlab chiqadi. Bundan tashqari, u midriazni teskari aylantirish, shuningdek, presbiopiya va xira yorug'lik yoki tungi ko'rish buzilishlarini davolash uchun Phentolamine Ophthalmic Solution va diabetik retinopatiyani davolash uchun Ref-1 ning kichik molekulali inhibitori bo'lgan APX3330ni ishlab chiqadi. Opus Genetics, Inc. ilgari Ocuphire Pharma, Inc. nomi bilan tanilgan va 2020-yil noyabr oyida Opus Genetics, Inc. nomini o'zgartirgan. Kompaniya 2018-yilda tashkil etilgan va Shimoliy Karolina shtatining Dyurham shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ashwath Jayagopal M.B.A., Ph.D. | Chief Scientific & Development Officer |
| Dr. Benjamin R. Yerxa Ph.D. | President & Director |
| Dr. George Magrath M.B.A., M.D., M.S. | CEO & Director |
| Mr. Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development & Secretary |
| Mr. Chris Ernst | Chief Technology Officer |
| Mr. Joseph K. Schachle MBA | Chief Operating Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 8-K | ird-20260512.htm |
| 2026-04-24 | 8-K | ef20071455_8k.htm |
| 2026-04-22 | 8-K | ef20071112_8k.htm |
| 2026-04-21 | S-3/A | ny20067725x2_s3a.htm |
| 2026-04-07 | 8-K | ef20069654_8k.htm |
| 2026-03-23 | DEF 14A | ny20063680x2_def14a.htm |
| 2026-03-23 | ARS | ny20063680x3_ars.pdf |
| 2026-03-13 | S-3 | ny20067725x1_s3.htm |
| 2026-03-12 | PRE 14A | ny20063680x1_pre14a.htm |
| 2026-03-12 | 10-K | ef20060643_10k.htm |
| Mr. Robert E. Gagnon CPA, M.B.A. | CFO & Principal Accounting Officer |
| Ms. Amy Zaremba Rabourn C.P.A., MAcc | Head of Financial Quality Assurance |
| Ms. Bindu Manne | Head of Market Development & Commercialization |
| Ms. Jenny Kobin | Investor Relations Officer |